Peloton partners with Respin Health to study exercise impact on menopause

NEW YORK - Peloton (NASDAQ:PTON), the fitness technology company currently valued at $3.4 billion with a robust gross profit margin of 51%, and Respin Health announced Monday a partnership to develop specialized fitness content for women experiencing perimenopause and menopause, alongside a research initiative to study how targeted exercise affects menopause-related symptoms.

The collaboration will begin this month with the PRESS (Peloton/Respin Exercise & Symptoms Study), involving 500 Peloton members who will receive access to workouts designed to address symptoms such as sleep disruption and energy fluctuations. The study will run through December with results expected in January 2026.

Following the research phase, the companies plan to launch the Peloton x Respin Menopause Care Program, which will make evidence-based exercise routines available to all Peloton members. The program will feature content from Peloton instructors Christine D’Ercole, Susie Chan, Joslyn Thompson Rule and Charlotte Weidenbach.

"Over the past year since I joined Peloton, I have heard from so many of our Members about the need for greater support during menopause," said Peter Stern, CEO of Peloton, according to the press release. The company’s strategic pivot comes amid strong recent performance, with InvestingPro data showing a 71% price return over the past six months and current liquidity metrics indicating the company’s liquid assets exceed short-term obligations.

Peloton will create a dedicated "Menopause Health" team on its platform to foster community engagement among participants.

Respin Health, founded by actress Halle Berry, focuses on personalized menopause care combining clinical research, coaching, and lifestyle resources.

The partnership launches during World Menopause Awareness Month, with study enrollment opening October 6.

In other recent news, Peloton Interactive has made significant announcements concerning its product lineup and technology enhancements. The company introduced Peloton IQ, an AI-powered personal coaching platform, which integrates with various digital platforms to offer personalized training plans. This new feature was part of a broader product portfolio overhaul that included the launch of the Cross Training Series, featuring upgraded models of the Bike, Bike+, Tread, Tread+, and Row+ with advanced features like swivel screens. Additionally, Peloton unveiled a new commercial equipment line called the Peloton Pro Series, designed for use in hotels, residential buildings, and corporate wellness centers.

Canaccord Genuity reiterated its Buy rating with a $10 price target, highlighting the potential of Peloton’s new AI features. Similarly, Goldman Sachs maintained its Buy rating and a price target of $11.50, expressing confidence in the company’s continued operating momentum. Meanwhile, Telsey Advisory Group raised its price target to $9 from $8, citing the comprehensive upgrades in Peloton’s product lineup. These developments reflect Peloton’s strategic focus on enhancing its product offerings and leveraging technology to maintain its competitive edge.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.